Atara Biotherapeutics Inc (NASDAQ:ATRA) Expected to Post Earnings of -$1.45 Per Share

Wall Street analysts expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to post earnings of ($1.45) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Atara Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($1.42) and the lowest estimate coming in at ($1.49). Atara Biotherapeutics reported earnings of ($1.15) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 26.1%. The business is expected to issue its next quarterly earnings results on Wednesday, August 7th.

On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($5.54) per share for the current year, with EPS estimates ranging from ($5.93) to ($5.21). For the next fiscal year, analysts anticipate that the business will report earnings of ($5.31) per share, with EPS estimates ranging from ($6.12) to ($4.63). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.48) by $0.04.

Several research firms have recently issued reports on ATRA. BidaskClub raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 7th. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, April 30th. Mizuho reissued a “buy” rating and issued a $62.00 price target on shares of Atara Biotherapeutics in a research note on Sunday, April 21st. ValuEngine raised Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 1st. Finally, William Blair reissued a “buy” rating on shares of Atara Biotherapeutics in a research note on Thursday, May 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the stock. Atara Biotherapeutics currently has an average rating of “Buy” and a consensus price target of $40.40.

NASDAQ:ATRA opened at $20.00 on Friday. Atara Biotherapeutics has a 1 year low of $19.95 and a 1 year high of $43.95. The stock has a fifty day simple moving average of $23.43. The company has a quick ratio of 9.96, a current ratio of 9.96 and a debt-to-equity ratio of 0.05.

In other news, insider Joe Newell sold 1,500 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $39.96, for a total value of $59,940.00. Following the completion of the sale, the insider now owns 63,646 shares in the company, valued at $2,543,294.16. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Isaac E. Ciechanover sold 3,900 shares of the company’s stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $37.04, for a total value of $144,456.00. Following the completion of the sale, the chief executive officer now owns 332,243 shares of the company’s stock, valued at approximately $12,306,280.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,150 shares of company stock valued at $1,147,091. Insiders own 7.00% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. FMR LLC increased its position in Atara Biotherapeutics by 21.7% in the 1st quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock worth $255,114,000 after purchasing an additional 1,143,787 shares during the last quarter. Redmile Group LLC increased its position in Atara Biotherapeutics by 1.6% in the 1st quarter. Redmile Group LLC now owns 4,485,417 shares of the biotechnology company’s stock worth $178,295,000 after purchasing an additional 70,800 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in shares of Atara Biotherapeutics during the 1st quarter valued at about $1,961,000. Marshall Wace LLP acquired a new position in shares of Atara Biotherapeutics during the 1st quarter valued at about $284,000. Finally, Neuberger Berman Group LLC increased its holdings in shares of Atara Biotherapeutics by 1.3% during the 1st quarter. Neuberger Berman Group LLC now owns 1,306,651 shares of the biotechnology company’s stock valued at $51,939,000 after acquiring an additional 16,703 shares during the last quarter.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Article: What is the downside to momentum investing?

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.